Regulatory Compliance Update Bulletin: Temperature Monitoring — May 2026
Regulatory Compliance Update Bulletin: Temperature Monitoring — May 2026
This bulletin summarises recent regulatory developments affecting temperature monitoring across food, pharmaceutical, and medical device supply chains in the US, Canada, the UK, Europe, and Australia/New Zealand. Temperature Indicators Ltd publishes these updates each month so quality managers, validation engineers, and compliance leads can stay informed of changes that may require updates to procedures, qualification protocols, or monitoring systems.
1. FDA Quality Management System Regulation (QMSR) Now in Force
The most significant medical device development of the period is the entry into force of the FDA's Quality Management System Regulation (QMSR), which took effect on 2 February 2026. The QMSR amends 21 CFR Part 820 by incorporating ISO 13485:2016 by reference, replacing the legacy device cGMP framework and harmonising FDA expectations with the international standard already used in most other regulated markets.
The QMSR applies to all manufacturers of finished medical devices marketed in the United States, including those producing devices that depend on temperature-controlled storage, transport, or sterilisation. On the same date the FDA retired the Quality System Inspection Technique (QSIT) and began conducting risk-based inspections under Compliance Program 7382.850, with focus areas now aligned to ISO 13485 clauses on environmental control, monitoring and measuring resources, and preservation of product.
Quality teams should review their environmental monitoring programmes against ISO 13485 clauses 6.4 (Work environment), 7.5.5 (Preservation of product), and 7.6 (Control of monitoring and measuring equipment). Calibration intervals for temperature data loggers, thermometers, and environmental sensors should be documented and traceable, and any references to 21 CFR Part 820 sub-sections in SOPs and supplier agreements should be updated to reflect the QMSR cross-references. See the official FDA Quality Management System Regulation (QMSR) page and the FDA QMSR FAQs.
2. FDA Food Traceability Rule Compliance Date Formally Extended to July 2028
The FDA Food Traceability Rule, codified at 21 CFR Part 1 Subpart S and issued under Section 204 of the Food Safety Modernization Act (FSMA), originally carried a compliance date of 20 January 2026. Following extensive industry feedback that supply-chain data systems were not yet interoperable enough to support the required Key Data Elements (KDEs) and Critical Tracking Events (CTEs), the FDA proposed a 30-month extension in August 2025. That extension has now been confirmed by the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act of 2026, which directs the FDA not to enforce the rule before 20 July 2028. The FDA has stated it intends to comply with the Congressional directive.
The rule applies to persons who manufacture, process, pack, or hold foods on the Food Traceability List (FTL), which includes many cold-chain-sensitive categories such as soft cheeses, deli salads, leafy greens, fresh-cut produce, finfish, crustaceans, molluscan shellfish, and ready-to-eat foods. Although enforcement has been pushed out, the substantive requirements of the rule have not changed: regulated firms must still capture and retain KDEs at each CTE and provide records to the FDA on request within 24 hours.
For quality and traceability teams, the extension is an opportunity rather than a reprieve. Pilot the recordkeeping workflow against current temperature monitoring data, confirm that lot-level traceability ties cleanly to time/temperature records, and verify that EDI partners and 3PLs can supply the data your systems will need. The FDA's official update is at FDA Proposes to Extend Compliance Date for Food Traceability Rule, and the rule's main page is at FSMA Final Rule on Requirements for Additional Traceability Records for Certain Foods.
3. USP General Chapter <1079.2> Mean Kinetic Temperature: Now Official, <1079.5> Proposed
The United States Pharmacopeia's revised General Chapter <1079.2> Mean Kinetic Temperature in the Evaluation of Temperature Excursions During Storage and Transportation became official on 1 August 2025 and is now embedded in Compendial expectations for the 2026 inspection cycle. For the first time, the chapter explicitly defines how mean kinetic temperature (MKT) should — and should not — be used to evaluate excursions, including defined calculation windows, temperature thresholds, documentation requirements, and warnings against common misuses such as masking short, high-magnitude excursions inside a long monitoring window.
The chapter applies to controlled room temperature (CRT) and controlled cold temperature (CCT) drug products, and the revision adds excursion limits for climatic zone IVb (hot and very humid). Distributors, wholesalers, and contract logistics providers shipping to such climates should review their excursion management SOPs to confirm alignment.
In parallel, USP has published a proposal for a new chapter <1079.5> Transportation Lane Temperature Mapping and Qualification in Pharmacopeial Forum 51(5), with the public-comment period closed in late 2025 and the final chapter expected to follow in 2026. The proposed chapter codifies expectations for how shipping lanes should be characterised, qualified, and re-qualified — an area where MHRA, EU, and Health Canada inspectors have already been pressing manufacturers for stronger evidence. Quality teams should monitor USP's USP-NF Notices page for the publication of the final <1079.5>, and review the existing <1079> series via the USP Supply Chain Integrity resources.
4. Health Canada GUI-0069: Broader Scope and "Environmental" Rather Than Just Temperature
Health Canada's revised GUI-0069 Guidelines for Environmental Control of Drugs During Storage and Transportation remains in force throughout 2026 and continues to be a focus of Health Canada inspections. The revision broadened the scope of the guidance in two important ways. First, responsibility for compliance is now formally assigned across all parties in the supply chain — product owners, third-party logistics providers (3PLs), carriers, importers, and distributors — rather than resting primarily with the marketing authorisation holder. Second, the term "environmental control" now expressly covers humidity, light, and physical stress in addition to temperature, recognising that many biologics and parenteral products are sensitive to factors beyond thermal exposure alone.
The guidance applies not only to human drugs but also to veterinary drugs, drugs used in clinical trials, drug samples, and active pharmaceutical ingredients (APIs). Quality teams importing into or distributing within Canada should ensure that their qualification protocols, transport validation studies, and supplier quality agreements explicitly address each environmental factor, and that 3PL contracts allocate responsibility unambiguously. The official guidance page is published by Health Canada at Health Canada GUI-0069 Guidelines for Environmental Control of Drugs During Storage and Transportation.
5. MHRA GDP: Continued Emphasis on Calibrated Monitoring and Risk-Based Mapping
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) refreshed its consolidated GDP guidance pages on GOV.UK in January 2026. There has been no wholesale revision of GDP principles, but the MHRA continues to emphasise three inspection areas: temperature mapping of warehouses and refrigerated areas at appropriate intervals, traceable annual calibration of monitoring devices against a reference standard, and documented control of cold-chain products at risk from freezing. On-site GDP inspections, which had largely been remote during the pandemic, have now fully resumed.
Wholesale dealers, brokers, and contract distributors holding a UK Wholesale Dealer Authorisation (WDA(H)) should ensure their qualification status remains current and that any changes in storage layout, racking density, or HVAC are reflected in re-mapping campaigns. See GOV.UK Medicines: GMP and GDP and the MHRA Inspectorate — Good Distribution Practice blog.
6. FSANZ Food Standards Code: Amendment No. 247 Published
Food Standards Australia New Zealand (FSANZ) gazetted Amendment No. 247 to the Australia New Zealand Food Standards Code on 20 January 2026 (FSC 187), and an updated compilation of the Code was published in March 2026. Amendment 247 principally updates permissions for specific substances and food technologies and does not introduce new numerical temperature limits; the long-standing temperature requirements in Standard 3.2.2 (Food Safety Practices and General Requirements) remain unchanged, including the requirement to keep potentially hazardous food at 5°C or colder, or 60°C or hotter, except where a documented alternative system is in place.
For Australian and New Zealand cold-chain operators, this is a useful prompt to confirm that monitoring devices, calibration records, and SOPs reference the current compilation. The amendment text is at FSANZ Amendment No. 247, and the consolidated Code is at FSANZ Food Standards Code legislation.
What This Means for Quality and Compliance Teams
The common thread running through this month's developments is convergence. The FDA's adoption of ISO 13485:2016 through the QMSR brings US medical device requirements into closer alignment with international expectations. Health Canada's revised GUI-0069 explicitly aligns with USP <1079> and FDA expectations, and the proposed USP <1079.5> on transportation lane qualification mirrors expectations already pursued by MHRA and EU inspectors. For organisations operating across multiple jurisdictions, this convergence reduces the friction of running parallel quality systems — but it also means that a weakness in one programme increasingly shows up across multiple inspection regimes.
Practically, May 2026 is a sensible point at which to review temperature mapping and re-qualification schedules, confirm calibration of every monitoring device is current and traceable, audit excursion management SOPs against the explicit MKT rules in USP <1079.2>, refresh supplier and 3PL responsibility matrices to reflect Health Canada's broader allocation of accountability, and update any 21 CFR Part 820 references in medical device SOPs to QMSR/ISO 13485:2016.
If your team is reviewing temperature-sensitive labels, irreversible threshold indicators, or time-temperature integrators as part of these workstreams, Temperature Indicators Ltd can help. Contact our team to discuss the most appropriate solution for your application.
Frequently Asked Questions
Does the FDA QMSR change the temperature monitoring requirements for medical device manufacturers?
The QMSR does not introduce new numerical temperature limits, but it does change the framework. By incorporating ISO 13485:2016, FDA inspections will now reference ISO clauses on work environment (6.4), preservation of product (7.5.5), and control of monitoring and measuring equipment (7.6). Manufacturers should ensure their environmental monitoring, calibration, and product preservation procedures map cleanly to these clauses and that legacy 21 CFR Part 820 references in SOPs have been updated.
Has the FDA Food Traceability Rule been cancelled?
No. The substantive requirements of the rule are unchanged. Only the enforcement compliance date has been extended from 20 January 2026 to 20 July 2028, following both an FDA-proposed extension and a Congressional directive in the 2026 Continuing Appropriations Act. Firms within scope should continue to build their Key Data Element capture and Critical Tracking Event records during the extended runway.
What is the most important change in USP <1079.2>?
For the first time the chapter sets explicit rules for how mean kinetic temperature (MKT) is used in excursion evaluation, including defined calculation windows, temperature thresholds, documentation requirements, and warnings against misuse — for example, using a long averaging window to mask a short high-temperature excursion. The revision also extends excursion limits to climatic zone IVb (hot and very humid).
Who is now responsible for cold chain compliance under Health Canada GUI-0069?
Responsibility is shared across the entire supply chain: product owners (marketing authorisation holders), third-party logistics providers, carriers, importers, and distributors all carry obligations under the revised guidance. Supplier quality agreements and 3PL contracts should explicitly allocate responsibility for environmental control — including humidity, light, and physical stress, as well as temperature.
About Temperature Indicators Ltd
Temperature Indicators Ltd is a global service provider specialising in temperature-sensitive labels, tags, and indicators for cold chain monitoring, process validation, and regulatory compliance. With 35 years of experience and warehouse stock in both the UK (Manchester) and the US (near Santa Barbara, California), we supply food manufacturers, pharmaceutical distributors, sterile services departments, and logistics providers worldwide with the temperature monitoring solutions they need to maintain compliance. Contact us for expert guidance on temperature monitoring for your application.
Legal Disclaimer
The information provided in this bulletin is intended for general informational purposes only and does not constitute legal, regulatory, or compliance advice. Regulatory requirements are subject to change and may vary by jurisdiction, product type, and business size. Organisations are responsible for ensuring their compliance with all applicable regulations. Temperature Indicators Ltd has made every effort to ensure the accuracy of the information presented based on publicly available sources as of the date of publication. This bulletin should not be relied upon as a substitute for independent legal or regulatory advice.
- Temperature Indicators Staff
